Clinical Trials for Mesothelioma Patients: NGR-hTNF

Read about a current clinical trial being conducted to study the effects of NGR-hTNF for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the study is currently being conducted only in Milan, Italy.

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (NGR010)

Objective: The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.

Requisite Conditions: Mesothelioma

Intervention: Drug: NGR-hTNF

Study Phase, Type and Description: Phase II Interventional Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study

Official Title: NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks in Patients Affected by Advanced or Metastatic Malignant Pleural

Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 27
State Date: May 2007
Estimated Completion Date: October 2008

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney